Game-Changer for Aggressive Colon Cancer

Big news for folks battling BRAF V600E-mutated metastatic colorectal cancer: the FDA just approved a new combo—Braftovi + Erbitux + chemo—as a first-line treatment! The BREAKWATER trial showed this mix bumps response rates up to 60% (vs. 40% with chemo alone). Translation: more patients are seeing their tumors shrink and feeling better, faster. If you or someone you know is dealing with this tough cancer, this could be a real lifeline. Testing for the BRAF mutation early is now more important than ever! #CancerResearch #FDAApproval #ColorectalCancer #BRAFMutation #MedicalBreakthrough #Health